Evaluation of the efficacy, safety and injection interval of intravitreal injection of ranibizumab for retinal vein occlusion

Evaluation of the efficacy, safety and injection interval of intravitreal injection of ranibizumab for retinal vein occlusion - intravitreal injection of ranibizumab for retinal vein occlusion

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012038

Enrollment

Registered

2013-10-15

Start date

2013-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

retinal vein occlusion

Interventions

Duration:12 months Quantity: ranibizumab 0.5 mg Bimonthly injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Outpatients of Shiga University of Medical Science Hospital with retinal vein occlusion that are examined by angiography or checked retinal thickness.

Exclusion criteria

Exclusion criteria: severe renal disease unstable angina malignant arrhythmia history of brain infarction history of cerebral hemorrhage severe hypertension

Design outcomes

Primary

Measure	Time frame
Variation on a logarithm of the minimum angle of resolution at 12 months after the first intravitreal injection	—

Secondary

Measure	Time frame
The rate of complication at 12 months after the first intravitreal injection Variation on a central retinal thickness	—

Countries

Japan

Contacts

Public ContactYoshitsugu Saishin

Shiga University of Medical Science Department of Ophthalmology

saishin@belle.shiga-med.ac.jp0775482276

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026